Drugs / albumin binding paclitaxel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05653453 Background | Dec 2022 → Dec 2026 expected | pancreatic neoplasm | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Recruiting | No outcome recorded |
| — | NCT06307080 Background | Oct 2023 → Dec 2025 overdue | malignant pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | albumin binding paclitaxel | “carreilizumab 200 mg IV D1+ gemcitabine 1000mg/㎡ IV+ albumin binding paclitaxel 125mg/㎡ IV D1.8Q3W; For 6 weeks” NCT06307080 ↗ |
| Route | Intravenous | “125 mg/m2 albumin binding paclitaxel will be administered intravenously” NCT05653453 ↗ |